Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 6/20 | 0.65 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.65 |
| ▸ | RAF1 | P04049 | 2/20 | 0.65 |
| ▸ | KDR | P35968 | 2/20 | 0.65 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.65 |
| ▸ | TGFBR2 | P37173 | 2/20 | 0.65 |
| ▸ | NEK2 | P51955 | 2/20 | 0.65 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.65 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.65 |
| ▸ | MAP2K5 | Q13163 | 2/20 | 0.65 |
| ▸ | PTK6 | Q13882 | 2/20 | 0.65 |
| ▸ | NEK11 | Q8NG66 | 2/20 | 0.65 |
| ▸ | MAP3K20 | Q9NYL2 | 2/20 | 0.65 |
| ▸ | MAP4K5 | Q9Y4K4 | 2/20 | 0.65 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.65 |
| ▸ | EGFR | P00533 | 1/20 | 0.65 |
| ▸ | KRAS | P01116 | 1/20 | 0.65 |
| ▸ | PGR | P06401 | 1/20 | 0.65 |
| ▸ | RET | P07949 | 1/20 | 0.65 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30582357 | 1.00 | BRAF (0.65) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL2354386 | 0.93 | BRAF (0.60) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL2886607 | 0.92 | CYP2C19 (0.66) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL3701742 | 0.92 | BRAF (0.59) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL3705271 | 0.92 | BRAF (0.60) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL21624516 | 0.91 | BRAF (0.55) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL3505554 | 0.91 | BRAF (0.57) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL3506948 | 0.90 | BRAF (0.56) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL2888839 | 0.90 | CYP2C19 (0.65) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL2891575 | 0.90 | CYP2C19 (0.68) | BRAFRIPK2RAF1KDRMAP2K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 333 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240115555-A1 | METHODS OF TREATING CANCER USING B-RAF INHIBITORS AND IMMUNE CHECKPOINT INHIBITORS | GENENTECH, INC. (US) | 2024-04-11 | — | — | US | claimed |
| US-20240046303-A1 | COMBINATION THERAPIES | GENENTECH INC (US) | 2024-02-08 | — | — | US | claimed |
| EP-4272735-A1 | IMMEDIATE-RELEASE TABLETS CONTAINING A DRUG AND PROCESSES FOR FORMING THE TABLETS | GENENTECH, INC. (US) | 2023-11-08 | — | — | EP | claimed |
| EP-3881833-B1 | IMMEDIATE-RELEASE TABLETS CONTAINING A DRUG AND PROCESSES FOR FORMING THE TABLETS | GENENTECH INC (US) | 2023-11-01 | — | — | EP | claimed |
| US-11783366-B2 | Combination therapies | GENENTECH, INC. (US) | 2023-10-10 | — | — | US | claimed |
| US-20220172244-A1 | COMBINATION THERAPIES | GENENTECH INC (US) | 2022-06-02 | — | — | US | claimed |
| CN-114177157-A | Immediate release tablet containing drug and method for forming tablet | 基因泰克公司 | 2022-03-15 | — | — | CN | claimed |
| EP-3881833-A1 | IMMEDIATE-RELEASE TABLETS CONTAINING A DRUG AND PROCESSES FOR FORMING THE TABLETS | Genentech, Inc. (US) | 2021-09-22 | — | — | EP | claimed |
| US-11087354-B2 | Combination therapies | GENENTECH, INC. (US) | 2021-08-10 | — | — | US | claimed |
| US-20200155520-A1 | METHODS OF TREATING CANCER USING B-RAF INHIBITORS AND IMMUNE CHECKPOINT INHIBITORS | GENENTECH, INC. (US) | 2020-05-21 | — | — | US | claimed |
| EP-2605764-A1 | COMBINATION ANTI - CANCER THERAPY | F.HOFFMANN-LA ROCHE AG (CH) | 2013-06-26 | — | — | EP | claimed |
| US-8470818-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2013-06-25 | — | — | US | claimed |
| WO-2013063001-A1 | THERAPEUTIC COMBINATIONS AND METHODS OF TREATING MELANOMA | GENENTECH, INC. (US) | 2013-05-02 | — | — | WO | claimed |
| WO-2012080151-A1 | COMBINATION THERAPY COMPRISING VEMURAFENIB AND AN INTERFERON FOR USE IN THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-21 | — | — | WO | claimed |
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. | 2012-05-17 | — | — | US | claimed |
| WO-2012022677-A2 | NOVEL COMBINATION THERAPY FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2012-02-23 | — | — | WO | claimed |
| WO-2012022724-A1 | COMBINATION ANTI - CANCER THERAPY | F. HOFFMANN-LA ROCHE AG (CH) | 2012-02-23 | — | — | WO | claimed |
| EP-1893612-B1 | PYRROLO [2, 3-B]PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON INC (US) | 2011-08-03 | — | — | EP | claimed |
| WO-2010129570-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. (US) | 2010-11-11 | — | — | WO | claimed |
| US-20100249118-A1 | protein kinase modulators such as Propane-1-sulfonic acid [2,4-difluoro-3-(5-ethoxy-1H-pyrrolo[1,3-b]pyridine-3-carbonyl)-phenyl]-amide, used to regulate signal transduction cascades, involved in the control of physiological functions including cellular growth and proliferation; anticarcinogenic agents | PLEXXIKON INC. | 2010-09-30 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249118-A1 | protein kinase modulators such as Propane-1-sulfonic acid [2,4-difluoro-3-(5-ethoxy-1H-pyrrolo[1,3-b]pyridine-3-carbonyl)-phenyl]-amide, used to regulate signal transduction cascades, involved in the control of physiological functions including cellular growth and proliferation; anticarcinogenic agents | MAP4K1, MAP4K2, MAP3K1 | BRAF 95/4885RIPK2 477/4885RAF1 36/4885 |
| US-20200155520-A1 | METHODS OF TREATING CANCER USING B-RAF INHIBITORS AND IMMUNE CHECKPOINT INHIBITORS | BRAF, RAF1, NRAS | BRAF 1/4885RIPK2 838/4885RAF1 2/4885 |
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | BRAF, RAF1, ARAF | BRAF 1/4885RIPK2 552/4885RAF1 2/4885 |
| US-20240046303-A1 | COMBINATION THERAPIES | HGF, MET, FGFR3 | BRAF 124/4885RIPK2 2518/4885RAF1 693/4885 |
| US-11783366-B2 | Combination therapies | HGF, MET, FGFR3 | BRAF 124/4885RIPK2 2518/4885RAF1 693/4885 |
| US-20220172244-A1 | COMBINATION THERAPIES | HGF, MET, FGFR3 | BRAF 124/4885RIPK2 2518/4885RAF1 693/4885 |
| US-11087354-B2 | Combination therapies | HGF, MET, FGFR3 | BRAF 124/4885RIPK2 2518/4885RAF1 693/4885 |
| US-20240115555-A1 | METHODS OF TREATING CANCER USING B-RAF INHIBITORS AND IMMUNE CHECKPOINT INHIBITORS | BRAF, RAF1, NRAS | BRAF 1/4885RIPK2 838/4885RAF1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.